Skip to content
DataLookout
Menu

NCT05683418

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 19 versions: 19 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 14 words
    • Trial sites expanded: 18 → 25 locations
  2. Notable Primary and study completion dates: Dec 2026 to Dec 2027v18 Show 7 more changesShow less
    • Eligibility criteria shortened, about 87 words
    • Interventions: TOS-358 (Drug) to Fulvestrant (Drug), Palbociclib (Drug), Ribociclib (Drug), TOS-358 (Drug)
    • Secondary endpoints expanded, about 6 words
    • Study sites revised (18)
    • Study arms: 1 to 3
    • Study description shortened, about 3 words
    • Study title shortened, about 4 words
  3. Notable Primary and study completion dates: Dec 2025 to Dec 2026v17 Show 4 more changesShow less
    • Eligibility criteria shortened, about 76 words
    • Study sites: 19 to 18
    • Study description shortened, about 23 words
    • Study title expanded, about 5 words
  4. Minor Study sites: 20 to 19v16
  5. Minor Study sites: 11 to 20v15
Show 13 earlier versionsHide 13 earlier versions
  1. Notable Eligibility criteria expanded, about 4 words
    • Study description shortened, about 13 words
    • Site contacts updated at 11 of 11 sites
    v14
  2. Minor Study sites: 16 to 11v13
  3. Minor Study sites: 12 to 16v12
  4. Minor Study sites: 11 to 12v11
  5. Minor Site contacts updated at 1 of 11 sitesv10
  6. Minor Study sites: 10 to 11v9
  7. Minor Study sites: 8 to 10v8
  8. Minor Study sites: 7 to 8v7
  9. Minor Study sites: 5 to 7v6
  10. Minor Study sites: 4 to 5v5
  11. Minor Study sites: 2 to 4v4
  12. Minor Study sites: 1 to 2v3
  13. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Feb 2023 to Feb 15, 2023
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Determine the rate of dose-limiting toxicities (DLTs)
Timeframe: First 21 days of treatment
Incidence and severity of adverse events (AEs) and specific laboratory abnormalities graded according to NCI CTCAE v5
Timeframe: Start of treatment to 30 days after last dose

Secondary (1)

ORR and duration of tumor control

Arms and interventions

TOS-358 + fulvestrantExperimental

TOS-358 + fulvestrant at standard dosing

TOS-358 + fulvestrant + CDK4/6iExperimental

TOS-358 + fulvestrant + CDK4/6i

TOS-358Experimental

PIK3CA covalent inhibitor

Drugs: TOS-358, Fulvestrant, Palbociclib, Ribociclib

Sites

25 sites in 2 countries

United States 16, Spain 9